May 2013,

“Nordion”) for the manufacture and supply of clinical trial material. The initial -year term expired in In in connection with the Company’s decision to refocus its resources, the Nordion agreement was amended to provide for a suspension period during which the Company was to pay a monthly fee to maintain production space at Nordion’s facility until such time as manufacture resumed. The Nordion agreement was terminated in Total purchases under the clinical supply agreement were and for the years ended and respectively.

August 2013,

“PETNET”) for the manufacture and distribution of The initial -year term of the agreement expired in and the agreement was renewed. Total purchases under the manufacturing agreement were and for the years ended and respectively.

September 2013,

“OsoBio”) for contract pharmaceutical development, manufacturing, packaging and analytical services for tilmanocept. Either party had the right to terminate the agreement upon mutual written agreement, or upon material breach by the other party if cured within days from the date of written notice of the breach. During the term of agreement, OsoBio was the primary supplier of manufacturing services for tilmanocept. In consideration for these services, the Company paid a unit pricing fee. In addition, the Company also paid OsoBio a fee for regulatory and other support services. Total purchases under the manufacturing services agreement were million and for the years ended and respectively. Upon closing of the Asset Sale to Cardinal Health our contract and open purchase orders with OsoBio were transferred to Cardinal Health

September 2013,

“Gipharma”) for process development, manufacturing and packaging of reduced-mass vials to be sold in the EU. The agreement had an initial term of years and automatically renewed for an additional -year periods. In consideration for these services, the Company paid fees as defined in the agreement. Total purchases under the service and supply master agreement were and for the years ended and respectively. Following the transfer of the tilmanocept Marketing Authorization to SpePharm, our contract with Gipharma was transferred to SpePharm.

closing of the Asset Sale to Cardinal Health the Company amended and restated its tilmanocept license agreement with UCSD pursuant to which UCSD granted a license to the Company to exploit certain intellectual property rights owned by UCSD and, separately, Cardinal Health entered into a license agreement with UCSD pursuant to which UCSD granted a license to Cardinal Health to exploit certain intellectual property rights owned by UCSD for Cardinal Health to sell the Product in the Territory. Pursuant to the Purchase Agreement, the Company granted to UCSD a ()-year warrant to purchase up to million shares of the Company’s common stock, par value per share, at an exercise price of per share.

July 2014,

executed an expanded license agreement for the exclusive world-wide rights to all diagnostic and therapeutic uses of tilmanocept (other than tilmanocept). The license agreement is effective until the anniversary of the expiration date of the longest-lived underlying patent. Under the terms of the license agreement, UCSD has granted us the exclusive rights to make, use, sell, offer for sale and import licensed products as defined in the agreement and to practice the defined licensed methods during the term of the agreement. We also sublicense the patent rights, subject to certain sublicense terms as defined in the agreement. As consideration for the license rights, we agreed to pay UCSD a license issue fee of and license maintenance fees of per year. We also agreed to make payments to UCSD upon successfully reaching certain clinical, regulatory and cumulative sales milestones, and a royalty on net sales of licensed products subject to a minimum annual royalty. In addition, we agreed to reimburse UCSD for all patent-related costs and to meet certain diligence targets. Total costs related to the UCSD license agreement for tilmanocept were and in and respectively, and were recorded in research and development expenses.

December 2011,

a proprietary compound that is primarily intended for use in diagnosing Alzheimer’s disease and other CNS disorders. The license agreement is effective until the later of the anniversary of the commercial sale of or the expiration of the underlying patents. Under the terms of the license agreement, AstraZeneca granted us an exclusive worldwide royalty-bearing license for with the right to grant sublicenses. In consideration for the license rights, we paid AstraZeneca a license issue fee of million upon execution of the agreement. We also agreed to pay AstraZeneca up to million in contingent milestone payments based on the achievement of certain clinical development and regulatory filing milestones, and up to million in contingent milestone payments due following receipt of certain regulatory approvals and the initiation of commercial sales of the licensed product. In addition, we agreed to pay AstraZeneca a royalty on net sales of licensed and sublicensed products. Total costs (adjustments) related to the AstraZeneca license agreement were $(), and in and respectively, and were recorded in research and development expenses.

July 2012,

NAV5001,

123

’s disease and other movement disorders, with a potential use as a diagnostic aid in dementia. Under the terms of the sublicense agreement, Alseres granted Navidea an exclusive, worldwide sublicense to research, develop and commercialize The terms of the agreement required Navidea to make a -time sublicense execution payment to Alseres equal to (i) in cash and (ii) shares of our common stock. The sublicense agreement also provided for contingent milestone payments of up to million, million of which would have principally occurred at the time of product registration or upon commercial sales, and the issuance of up to an additional million shares of Navidea common stock, shares of which would have been issuable at the time of product registration or upon commercial sales. In addition, the sublicense terms anticipated royalties on annual net sales of the approved product which were consistent with industry-standard terms and certain sublicense extension fees, payable in cash and shares of common stock, in the event certain diligence milestones were met. In the Company entered into an agreement with Alseres to terminate the Alseres sublicense agreement. Under the terms of this agreement, Navidea transferred all regulatory, clinical and manufacturing-related data related to to Alseres. Alseres agreed to reimburse Navidea for any incurred maintenance costs of the contract manufacturer retroactive to In addition, Navidea has supplied clinical support services for on a cost-plus reimbursement basis. However, to this point, Alseres has been unsuccessful in raising the funds necessary to restart the program and reimburse Navidea. As a result, we have taken steps to end our obligations under the agreement and notified Alseres that we consider them in breach of the agreement. To date, we have been successful in our efforts to recover the funds we expended complying with our obligations under the termination agreement. Total costs related to the Alseres sublicense agreement were and in and respectively, and were recorded in research and development expenses.